Interferon alfa for neovascular age-related macular degeneration
Sübutlu məlumatların xülasələri
28.12.2015 • Sonuncu dəyişiklik 28.12.2015
Editors
Interferon alfa-2a appears not to be beneficial for the treatment of age-related macular degeneration and may even have harmful effects.
A Cochrane review included one study with a total of 481 subjects. The odds ratio for losing three or more lines of vision at 52 weeks with interferon alfa-2a versus placebo was 1.60 (95% CI 1.01 to 2.53), i.e., interferon was associated with a 60% increased odds of decreased visual acuity (p=0.04).
Comment: The quality of evidence is downgraded by imprecise results (one single study).
Ədəbiyyat
- Reddy U, Kryzstolik M. Antiangiogenic therapy with interferon alfa for neovascular age-related macular degeneration. Cochrane Database Syst Rev 2006 Jan 25;(1):CD005138.